CBIO vs GILD
CBIO: A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors. GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments.
Side-by-side fundamentals
| Metric | CBIO | GILD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $14.12 | $147.10 | |
| Market cap | $524M | $182.4B | |
| Net margin FY2025, SEC XBRL | -1419.6% | +28.9% | GILD higher |
| Operating margin FY2025, SEC XBRL | -1407.5% | +34.0% | GILD higher |
| ROE FY2025, SEC XBRL | -75.8% | +37.6% | GILD higher |
| ROA FY2025, SEC XBRL | -64.1% | +14.4% | GILD higher |
| Debt / equity as of 2026-09-03 | 0.00 | 2.22 | CBIO lower |
| Revenue growth (YoY) as of 2026-09-03 | +413.7% | +5.5% | CBIO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.6% | |
| Dividend yield as of 2026-09-03 | n/a | +2.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 11 | |
| Beta as of 2026-09-03 | 1.10 | 0.37 | |
| 1-year return as of 2026-10-08 close | +17.1% | +24.4% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.